Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
about
Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypesTreatment of Acute Myeloid Leukemia in Adolescent and Young Adult PatientsVolasertib for AML: clinical use and patient considerationCore Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesPost-remission therapy for acute myeloid leukemiaProgress in acute myeloid leukemiaTargeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemiaRelapsed acute myeloid leukemia: why is there no standard of care?Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemiaHigh-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisDNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B studyTime from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patientsAdvances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaPossible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemiaFludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort studyCauses of oncogenic chromosomal translocation.Runx1 loss minimally impacts long-term hematopoietic stem cellsSequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapyRetrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.Impact of residual normal metaphases in core binding factor acute myeloid leukemiainv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study.Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readoutsThe role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseLow WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.Cure models as a useful statistical tool for analyzing survival.Is it important to decipher the heterogeneity of "normal karyotype AML"?Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group.Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
P2860
Q24811346-56950F1F-B420-4392-9A53-BE9F38B42BE1Q26799609-C75ECC1E-C2EA-426E-AF62-39D2729D6F7DQ26801131-25862941-BB69-4DF1-88E0-1CDC7E5224CBQ26863756-7DDD7DE6-7D0C-4D21-A5FF-BAAAC5D1C4A4Q26995867-245BE9D3-3BC5-4D67-9116-B157B89DC00CQ27024006-5309A05A-E75E-4396-83D8-A3FDB35D21A6Q30622245-377983E5-4DDF-4494-A1D5-1ED67AA9B0A6Q33877202-15170F1F-864B-4ABA-A6DD-2850CFB34375Q33903024-A05F572C-6873-4523-9AB8-BE7AC7CCDDA8Q33949752-ADF8FAA5-FE98-4ED7-B9EE-C23BBD44F6AFQ34285901-E0ABE08E-FA90-4A0A-9860-132BCFCDC570Q34316768-29CF5A95-E4D3-4BA8-9411-759972C02197Q34317679-0EBCB8BC-F6DE-4EBA-B5A7-CB86BB1D9109Q34386755-2E8DBC2F-F631-4D26-B9A0-B7C31559C2D4Q34428556-1ADB415C-30BE-427B-AF34-0100ED5EBF0CQ34433577-48C4D2ED-1EE8-4303-8967-3EFA5212596CQ34457438-5130351E-2269-49B2-9B97-9AE783882A1AQ34593276-DA495CA3-DDDD-4E17-A00B-B5BD30D87E76Q34597777-7DD877AB-1F37-4D71-82DD-C13DF0C96358Q34598109-7A68D92A-68DA-4DD1-B670-2F9D388730F6Q35062514-05973382-D7DC-4F5E-A4F5-9734A8D46219Q35142616-E04ACE76-EAAD-4F62-B71D-9834E5EEF878Q35286194-5AEA67BE-63B8-4056-9741-67D69B0B148AQ35570942-EEBB35AB-7B68-4733-B7E7-5B06C4FE3F21Q35586823-8DCC0258-717E-4AD5-826E-163CEA353DCCQ35847482-93381BF6-26B7-4CE1-AFA8-1CE695C6EB7FQ35849784-E82D3558-F6D9-4451-9AF6-DBB7C3EF4F53Q35937101-93A4067E-5849-4AF0-8489-730A0A9FBA20Q36065836-DEC88004-519E-448F-BD1F-A81838F430FFQ36152664-997307DB-258C-4ADE-AF63-382AAFEBB834Q36375411-76174E19-A8DE-40AC-B37B-16CB4B6DE052Q36529502-3429B576-CEC3-487E-B176-508968269626Q36579101-F3488807-6B18-4A09-8E29-5BDB74636145Q36784704-3C759137-C044-46D4-9CE8-12515F57608AQ36788138-D68CDC57-10F2-4579-9FDF-41E008554088Q36919799-C8297744-6F1D-41A2-B1D6-A500970AF44AQ37096671-E89165D0-5EE3-4DF9-BDA2-61B1B4F36777Q37110802-BA6DA2CD-BAF0-46AC-8548-8B324C9AFBC6Q37149438-D97216F6-3812-4A52-A109-DFF9FB3B0008Q37199950-08D16FF3-7010-41AC-AFF9-E88335F698A5
P2860
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@ast
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@en
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@nl
type
label
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@ast
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@en
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@nl
prefLabel
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@ast
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@en
Frequency of prolonged remissi ...... varies by cytogenetic subtype.
@nl
P2093
P1433
P1476
Frequency of prolonged remissi ...... varies by cytogenetic subtype
@en
P2093
Bloomfield CD
Lawrence D
Pettenati MJ
P304
P407
P577
1998-09-01T00:00:00Z